Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | A. Basis of Presentation and Summary of Significant Accounting Policies The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10 three September 30, 2024 not You should read the financial statements and these notes, which notes are an integral part of the financial statements, together with our audited financial statements included in our Annual Report on Form 10 June 30, 2024 “2024 2024 Recently Adopted Accounting Pronouncements We did not three September 30, 2024 Recently Issued Accounting and Regulatory Pronouncements In November 2024, 2024 03, 220 40 2024 03 December 15, 2026, December 15, 2027. 2024 03 2024 03, June 30, 2028. not Net Loss per Common Share We compute net loss per common share using the weighted average number of common shares outstanding during the period, and diluted net loss per common share using the additional dilutive effect of all dilutive securities. The dilutive impact of unvested restricted shares accounts for the additional weighted average shares of common stock outstanding for our diluted net loss per common share computation. We calculated basic and diluted net loss per common share as follows (in thousands, except per share data): Three Months Ended September 30, 2024 2023 Numerator Net loss $ (1,982 ) $ (695 ) Denominator Basic weighted average common shares outstanding 5,919 5,850 Dilutive effect of restricted stock — — Diluted weighted average common shares outstanding 5,919 5,850 Basic net loss per common share $ (0.33 ) $ (0.12 ) Diluted net loss per common share $ (0.33 ) $ (0.12 ) We exclude the impact of restricted stock from the calculation of diluted net loss per common share in periods where we have a net loss or when their inclusion would be antidilutive. During the three September 30, 2024 three September 30, 2023 Revenue Recognition We record revenue based on a five 1 2 3 4 5 Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling one 30 Revenue is recognized at the point in time that each of our performance obligations is fulfilled, and control of the ordered products is transferred to the customer. This transfer occurs when the product is shipped, or in some cases, when the product is delivered to the customer. We recognize revenue in certain circumstances before delivery to the customer has occurred (commonly referred to as bill-and-hold transactions). Products sold under bill-and-hold arrangements are recorded as revenue when risk of ownership has been transferred to the customer, but the product has not We provide early payment discounts to certain customers. Based on historical payment trends, we expect that these customers will take advantage of these early payment discounts. The cost of these discounts is reported as a reduction to the transaction price. If the actual discounts differ from those estimated, the difference is also reported as a change in the transaction price. We require prepayment from certain customers. We record any payments received in advance of contract fulfillment as a contract liability and they are classified as customer deposits on the consolidated balance sheet. Contract liabilities and revenue recognized were as follows (in thousands): June 30, 2024 Additions Revenue Recognized Customer Refunds September 30, 2024 Contract Liabilities (Customer Deposits) $ 302 $ 1,113 $ (779 ) $ — $ 636 June 30, 2023 Additions Revenue Recognized Customer Refunds September 30, 2023 Contract Liabilities (Customer Deposits) $ 317 $ 413 $ (325 ) $ — $ 405 Except for product defects, no September 30, 2024 We currently own certain U.S. patents, and each patent’s corresponding foreign patent applications. All of these patents and patent rights relate to the ingredient known as beta-alanine marketed and sold under our CarnoSyn® and SR CarnoSyn® trademarks, and our TriBysn™ tradename. We recorded beta-alanine raw material sales and royalty and licensing income as a component of revenue in the amount of $2.5 million during the three September 30, 2024 three September 30, 2023 three September 30, 2024 three September 30, 2023 Stock-Based Compensation The Board of Directors approved our current omnibus equity incentive plan that became effective January 1, 2021 ( “2020 2020 December 4, 2020. 2020 may We did not three September 30, 2024 September 30, 2023 We did not three September 30, 2024 three September 30, 2023 three September 30, 2024 September 30, 2023 no three September 30, 2024 September 30, 2023 Deferred Compensation Plan Effective July 16, 2020, may The Incentive Plan authorizes the Human Resources Committee or the Board of Directors to grant to, and administer, unsecured and deferred cash Awards to Participants and to subject each Award to whatever conditions are determined appropriate by the Human Resources Committee or the Board of Directors. The terms of each Award, including the amount and any conditions that must be met to be entitled to payment of the Award are set forth in an Award Agreement between each Participant and NAI. The Incentive Plan provides the Board of Directors with the discretion to set aside assets to fund the Incentive Plan although that has not No three September 30, 2024 September 30, 2023 Fair Value of Financial Instruments Except for cash and cash equivalents, as of September 30, 2024 June 30, 2024 not 1. 2 third Fair value of derivative instruments classified as Level 2 September 30, 2024 June 30, 2024 Interest Swap–Other Current Assets $ — $ 111 Euro Forward Contract– Current Assets — 492 Swiss Franc Forward Contract – Current Assets 31 — Total Derivative Contracts – Current Assets 31 603 Euro Forward Contract– Other noncurrent Assets — 78 Total Derivative Contracts – Other noncurrent Assets — 78 Euro Forward Contract– Current Liabilities (543 ) — Swiss Franc Forward Contract – Current Liabilities — (91 ) Total Derivative Contracts – Current Liabilities (543 ) (91 ) Fair Value Net Asset – all Derivative Contracts $ (512 ) $ 590 We also classify any outstanding line of credit and term loan balance as a Level 2 September 30, 2024 one June 30, 2024 September 30, 2024 June 30, 2024 not 3. not 2025 2024. |